Revolution Medicines (RVMD) Depreciation & Amortization (CF) (2019 - 2026)

Revolution Medicines' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 38.65% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $8.4 million (up 25.67% YoY), while the FY2025 annual figure was $7.8 million, up 18.62% from the prior year.
• Depreciation & Amortization (CF) was $2.3 million for Q1 2026 at Revolution Medicines, up from $2.3 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.3 million in Q1 2026 to a low of $901000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $1.5 million across 5 years, with a median of $1.5 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) gained 7.06% in 2025, then soared 38.65% in 2026.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.1 million in 2022, then grew by 13.14% to $1.3 million in 2023, then soared by 33.46% to $1.7 million in 2024, then soared by 30.66% to $2.3 million in 2025, then gained by 3.48% to $2.3 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $2.3 million (Q1 2026), $2.3 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.